Société Française de Thérapie Cellulaire et Génique

Société Française de Thérapie Cellulaire et Génique La SFTCG est une organisation à but non lucratif qui représente les intérêts des scientifiques concernés par le développement de nouvelles thérapies.
(1)

La Société Française de Thérapie Cellulaire et Génique est une organisation à but non lucratif qui représente les intérêts des scientifiques concernés par le développement de nouvelles thérapies cellulaires et géniques. La Société a pour mission la promotion du progrès thérapeutique dans le domaine des biothérapies, de la médecine régénérative, des technologies basées sur le transfert de gènes et la biologie cellulaire pour les maladies de tous types, génétiques ou acquises : maladies métaboliques, musculaires, neurologiques, cardio-vasculaires, cutanées, hématologiques, immunologiques, cancer et maladies infectieuses.

Fonctionnement normal

ESGCT e-school join us on Wednesday at 14:00 CEST
12/10/2020

ESGCT e-school join us on Wednesday at 14:00 CEST

Join us on Wednesday 14 October at 14:00 CEST for the first talk in series 6 - CNS gene therapy
Nathalie Cartier, ICM, Inserm, France will be live on YouTube (www.youtube.com/c/ESGCTvideo)
The CNS - gene therapy for Alzheimer's disease and beyond

European Society for Gene and Cell Therapy
07/10/2020

European Society for Gene and Cell Therapy

Many congratulations to Emmanuelle Charpentier and Jennifer Doudna who were awarded the #Nobel Prize in Chemistry this morning for the discovery of #CRISPR/Cas9.

ESGCT e-school join us on Wednesday at 14:00 CEST
06/10/2020

ESGCT e-school join us on Wednesday at 14:00 CEST

Join us on Wednesday 7 October at 14:00 CEST for the final talk in series 5 - Gene & cell therapy of rare diseases
Juan Bueren, División de Terapias Innovadoras en el Sistema Hematopoyético CIEMAT will be live on YouTube (www.youtube.com/c/ESGCTvideo)
Bone marrow failure syndromes: Fanconi anemia, a Stem Cell Disease

ESGCT e-school - please join us on Wednesday 30 September at 14:00 CEST
29/09/2020

ESGCT e-school - please join us on Wednesday 30 September at 14:00 CEST

Join us on Wednesday 30 September at 14:00 CEST for the 2nd talk in series 5 - Gene & cell therapy of rare diseases
Giuliana Ferrari, San Raffaele Telethon Institute for Gene Therapy will be live on YouTube (www.youtube.com/c/ESGCTvideo)- Beta Thal – the long way to cure

ESGCT e-school this week is on THURSDAY 24 September at 14:00 CEST - please join us
22/09/2020

ESGCT e-school this week is on THURSDAY 24 September at 14:00 CEST - please join us

This week ESGCT e-School is on THURSDAY 24 September at 14:00 CEST

Join us for the first talk in series 5 - Gene & cell therapy of rare diseases

Alessandro Aiuti, San Raffaele Telethon Institute for Gene Therapy IRCCS Ospedale San Raffaele and Vita Salute San Raffaele University, Milan will be live on YouTube (www.youtube.com/c/ESGCTvideo)- 25 years of experience of gene therapy for ADA-SCID: brining a medicinal product to approval

We have decided to further extend the deadline to send us a motivational video, PPT or poster about gene and cell therap...
21/09/2020

We have decided to further extend the deadline to send us a motivational video, PPT or poster about gene and cell therapy. This competition is open to students and postdoctoral fellows.
More information can be found on our website, https://www.sftcg.fr/Concours.aspx, deadline October 15.

Please join us for the ESGCT e-school Wednesday 16 September at 14:00 CEST
14/09/2020

Please join us for the ESGCT e-school Wednesday 16 September at 14:00 CEST

ESGCT e-School: Join us for the final talk in series 4 - Safety aspects of gene therapy and gene editing
Wednesday 16 September at 14:00 CEST, Claire Booth, UCL Institute of Child Health, London will be live on YouTube (www.youtube.com/c/ESGCTvideo)- Genotoxicity - what we have learnt from SCID-X1 and about next generation tools for PID

ESGCT e-school - join  us on Wednesday 9 September at 14:00 CEST
07/09/2020

ESGCT e-school - join us on Wednesday 9 September at 14:00 CEST

ESGCT e-School: Join us for the 2nd talk in series 4 - Safety aspects of gene therapy and gene editing

Wednesday 9 September at 14:00 CEST, Anne Galy, Généthon Èvry will be live on YouTube (www.youtube.com/c/ESGCTvideo)- Immunogenicity - the challenge of our own security system

Join the ESGCT e-school Wednesday 29 July at 14:00 CEST
27/07/2020

Join the ESGCT e-school Wednesday 29 July at 14:00 CEST

ESGCT e-School: Join us for the 3rd talk in series 3 - The genetic payload
Wednesday 29 July at 14:00 CEST, Benjamin Kleinstiver,
Center for Genomic Medicine, Massachusetts General Hospital, Boston will be live on YouTube (www.youtube.com/c/ESGCTvideo)- Nucleases used for gene editing

Join the ESGCT e-school Wednesday 22 July at 14:00 CEST
20/07/2020

Join the ESGCT e-school Wednesday 22 July at 14:00 CEST

ESGCT e-School: Join us for the 2nd talk in series 3 - The genetic payload
Wednesday 22 July at 14:00 CEST, Daniel E. Bauer
Boston Children's Hospital will be live on YouTube (www.youtube.com/c/ESGCTvideo)- Knock-out, Knock-in, repair or regulate - the tool-box of designer nucleases

Join the ESGCT e-school Wednesday 15 July at 14.00 CEST
13/07/2020

Join the ESGCT e-school Wednesday 15 July at 14.00 CEST

ESGCT e-School: Join us for the 1st talk in series 3 - The genetic payload
Wednesday 15 July at 14:00 CEST, Alberto Auricchio,
Tigem Naples will be live on YouTube (www.youtube.com/c/ESGCTvideo)- How to teach a small virus to go over its limit

Join the ESGCT e-school Wednesday 8 July at 14.00 CEST
06/07/2020

Join the ESGCT e-school Wednesday 8 July at 14.00 CEST

ESGCT e-School: Join us for the 2nd talk in series 2 - Vector Production.
Wednesday 8 July at 14:00 CEST, Eduard Ayuso
University of Nantes will be live on YouTube (www.youtube.com/c/ESGCTvideo)- What you should know about producing AAV vectors

Join the ESGCT e-school Wednesday 1 July at 14.00 CEST
29/06/2020

Join the ESGCT e-school Wednesday 1 July at 14.00 CEST

ESGCT e-School: Series 2 - Vector Production
Wednesday 1 July at 14:00 CEST, Hanna Lesch
Kuopio Center for Gene and Cell Therapy will be live on YouTube (www.youtube.com/c/ESGCTvideo)- What you should know about producing gamma and lentiviral vectors

Please join the ESGCT e-School on Wednesday 24 June
22/06/2020

Please join the ESGCT e-School on Wednesday 24 June

ESGCT e-School: this week, on Wednesday 24 June at 14:00 CEST, Urs Greber from University of Zurich will be live on YouTube (www.youtube.com/c/ESGCTvideo) for the final e-school session in Series 1 - Learn from viruses to improve viral and non-viral vectors.

Next week Series 2 will commence on Vector Production

Please join the ESGCT e-school and e-seminar this Wednesday 17 June
16/06/2020

Please join the ESGCT e-school and e-seminar this Wednesday 17 June

ESGCT e-School: this week, on Wednesday 17 June at 14:00 CEST, Drew Weissman from University of Pennsylvania will be live on YouTube (www.youtube.com/c/ESGCTvideo) for the penultimate e-school session in Series 1 - Synthetic vectors – to take the best from viruses and go beyond

Followed at 15:00 CEST by the final talk of our e-Seminar series by Stefan Pöhlmann from Deutsches Primatenzentrum, Göttingen with a talk on SARS-CoV2 – spotlight on cell entry

Please join the ESGCT e-school and e-seminar this Wednesday 10 June
08/06/2020

Please join the ESGCT e-school and e-seminar this Wednesday 10 June

ESGCT e-School: this week, on Wednesday 10 June at 14:00 CEST, Zoltan Ivics from Paul Elrich Institute, Langen will be live on YouTube (www.youtube.com/c/ESGCTvideo) for the 5th e-school session in Series 1 with a talk titled: Sleeping beauty transposase – to learn from nature.

Followed at 15:00 CEST by the 3rd talk of our e-Seminar by Ami Patel from The Wistar Institute, Philadelphia, PA with a talk on Novel vaccine strategies targeting SARS-CoV2

04/06/2020
ESGCT e-Seminar: The Covid-19 pandemic

Want to know more about the Covid-19 pandemic? Missed the live talk by Daniel Lucey yesterday? You can still catch it on YouTube..

Speaker: Daniel Lucey, O’Neill Institute for National and Global Health Law, Washington DC Chair: Hildegard Büning, Hannover Medical School

04/06/2020
Die Seite wurde nicht gefunden | Else Kröner-Fresenius-Stiftung

We are very happy to announce the winner of the Else Kröner Fresenius Prize for Medical Research 2020 Genome Editing and Gene Therapy

Alessandro Aiuti MD, PhD, San Raffaele Telethon Institute for Gene Therapy, IRCCS Ospedale San Raffaele and Vita Salute San Raffaele University, Milan

for his groundbreaking contributions to the advancement of therapies for immunodeficiencies and other genetic diseases.

Please watch the video spot on our website: www.ekfs.de/…/else-kroener-fresenius-prize-for-medical-rese…

Image © Fondazione Telethon / Else Kröner-Fresenius-Stiftung

Please join the ESGCT e-school and e-seminar this Wednesday 3 June
01/06/2020

Please join the ESGCT e-school and e-seminar this Wednesday 3 June

ESGCT e-School: this week, on Wednesday 3 June at 14:00 CEST, Hildegard Büning from Hannover Medical School will be live on YouTube (www.youtube.com/c/ESGCTvideo) for the 4th e-school session in Series 1 with a talk on Adeno-associated virus (AAV) vectors – to teach an old virus new tricks

Followed at 15:00 CEST by the 2nd talk of our e-Seminar by Daniel Lucey from O’Neill Institute for National and Global Health Law, Washington DC with a talk on The Covid-19 pandemic

La SFTCG est maintenant sur Instagram ! Venez nous suivre pour suivre nos actualités et événements en photos ! 🧬(@sftcgo...
30/05/2020

La SFTCG est maintenant sur Instagram ! Venez nous suivre pour suivre nos actualités et événements en photos ! 🧬
(@sftcgofficiel on Instagram)

La SFTCG lance un concours pour vulgariser et expliquer la thérapie cellulaire ou générique au  grand public. Si vous êt...
30/05/2020

La SFTCG lance un concours pour vulgariser et expliquer la thérapie cellulaire ou générique au grand public.
Si vous êtes un postdoc ou un étudiant motivé, venez prendre part à ce concours et tentez de remporter un prix ! 🧬
Date limite de soumission: 30 Août 2020
Plus d'infos sur: https://www.sftcg.fr/Concours.aspx

@SFTCG is launching a competition to popularize and explain cell and gene therapy to the general public.
You're a motivated postdoc or student, come and take part in this competition to try and win a price ! 🧬
Deadline: 30st August 2020
More info on: https://www.sftcg.fr/Concours.aspx

29/05/2020
ESGCT e-Seminar: Current insights on the origin of SARS-CoV2

If you did not watch our first e-Seminar live... you can catch up on this extremely interesting talk on the origin of SARS-CoV2 by Dong Yan Jin from The University of Hong Kong on the ESGCT YouTube Channel

Speaker: Dong-Yan Jin, The University of Hong Kong Chair: Hildegard Büning, Hannover Medical School

ESGCT e-School: this week, on Wednesday 27 May at 14:00 CEST, Len Seymour from Oxford University will be live on YouTube...
25/05/2020

ESGCT e-School: this week, on Wednesday 27 May at 14:00 CEST, Len Seymour from Oxford University will be live on YouTube (www.youtube.com/c/ESGCTvideo) for the 3rd e-school session in Series 1 with a talk on Adenoviral vectors – gene delivery tool, powerful weapon in cancer and beyond

Followed at 15:00 CEST by the first talk of our e-Seminar on the SARS-CoV2 pandemic by Dong-Yan JIN from The University of Hong Kong with a talk on the Current insights on the origin of SARS-CoV2

Novartis et sa filiale Avexis ont obtenu une approbation conditionnelle par la FDA pour la commercialisation de la théra...
21/05/2020
ZOLGENSMA® (onasemnogene abeparvovec-xioi)

Novartis et sa filiale Avexis ont obtenu une approbation conditionnelle par la FDA pour la commercialisation de la thérapie génique Zolgensma® (onasemnogene abeparvovec) destinée aux bébés et enfants atteints d’amyotrophie spinale (AMS). Son accès est désormais possible en France et devrait l’être prochainement en Allemagne. En Europe, environ 550 à 600 nourrissons naissent avec cette maladie neuromusculaire génétique. Avexis précise être en discussion avec les gouvernements européens et les agences de remboursement pour convenir des termes du programme d’accès Day One, afin de “permettre un accès rapide dans tous les pays de l’UE ayant un besoin urgent de traiter l’AMS.

Pour en savoir plus sur cette thérapie génique : https://www.zolgensma.com/how-zolgensma-works

See the Indication, Safety, & Prescribing Information.

N'oubliez pas le mercredi 20 May de rejoindre l'ESGCT sur YouTube (www.youtube.com/c/ESGCTvideo) pour la présentation de...
18/05/2020

N'oubliez pas le mercredi 20 May de rejoindre l'ESGCT sur YouTube (www.youtube.com/c/ESGCTvideo) pour la présentation de notre Présidente

Els Verhoeyen
University of Nice and University of Lyon

How to teach enveloped vectors about cell entry targeting

Chair: Hildegard Büning, Hannover Medical School

Société Française de Thérapie Cellulaire et Génique's cover photo
11/05/2020

Société Française de Thérapie Cellulaire et Génique's cover photo

Société Française de Thérapie Cellulaire et Génique's cover photo
11/05/2020

Société Française de Thérapie Cellulaire et Génique's cover photo

Article intéressant et prometteur sur l’utilisation de CRISPR-Cas9 pour le traitement du diabiète 🧬https://stm.sciencema...
03/05/2020
Gene-edited human stem cell–derived β cells from a patient with monogenic diabetes reverse preexisting diabetes in mice

Article intéressant et prometteur sur l’utilisation de CRISPR-Cas9 pour le traitement du diabiète 🧬https://stm.sciencemag.org/content/12/540/eaax9106/tab-article-info

Wolfram syndrome is a recessive genetic disease caused by mutations in WFS1 (Wolfram syndrome 1) and can present with a multitude of symptoms including diabetes, optic atrophy, and neurological problems. There is currently no cure and patients are managed with symptomatic treatment. Maxwell et al .....

En pleine actualité du Covid19, voici une review très intéressante sur les essais cliniques initiés en Chine sur l’utili...
26/04/2020
Mesenchymal Stem Cell Therapy for COVID-19: Present or Future

En pleine actualité du Covid19, voici une review très intéressante sur les essais cliniques initiés en Chine sur l’utilisation de cellules souches mesenchymases pour moduler la réponse immune au Sars-Cov2 et également des essais pour évaluer la régénération des poumons.
Bonne lecture 🦠🔬📚

https://link.springer.com/article/10.1007%2Fs12015-020-09973-w

“COVID-19” is the word that certainly isn’t forgotten by everybody who lives in the first half of the twenty-first century. COVID-19, as a pandemic, has led many researchers from different biomedical fields to find solutions or treatments to manage the pandemic. However, no standard treatment ...

08/04/2020

Malheureusement, à cause de la situation sanitaire actuelle liée au Covid19 nous avons été forcé de reporter notre congrès qui devait avoir lieu du 11 au 13 Mars à Lyon. Sans beaucoup de visibilité actuellement nous réfléchissons à une nouvelle date pour la tenue du congrès, que nous vous communiquerons dès qu'elle sera fixée.
Restons tous solidaires pour sortir au plus vite de cette crise sanitaire, soulager le personnel soignant et tous ceux qui agissent au quotidien pour lutter contre cette épidémie. #stayhome #celltherapy #genetherapy

Adresse

Paris
75335

Notifications

Soyez le premier à savoir et laissez-nous vous envoyer un courriel lorsque Société Française de Thérapie Cellulaire et Génique publie des nouvelles et des promotions. Votre adresse e-mail ne sera pas utilisée à d'autres fins, et vous pouvez vous désabonner à tout moment.

Contacter L'entreprise

Envoyer un message à Société Française de Thérapie Cellulaire et Génique:

Organisations à But Non Lucratifss á proximité


Autres Organisation à but non lucratif à Paris

Voir Toutes

Commentaires

I'm looking for a gene therapy specialist to work with him on a project